EUVIMEDEUVIMED entdecken
Crossref

Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors

Yutaro Miura, Kohei Tsuji iD, Takuya Kobayakawa, Kaho Matsumoto, Takeo Kuwata, Riku Matsuzaki, Shuzo Matsushita, Hirokazu Tamamura iD

Journal of Medicinal Chemistry · 25.12.2025 · 68 (24) · 25899-25911

DOI: 10.1021/acs.jmedchem.5c01552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 15.12.2025. Verfasst von Yutaro Miura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kandasurugadai, Chiyoda-ku, Toky…. Hauptthemen laut MEDLINE: CD4 Antigens, HIV-1, Immunoconjugates, Antibodies, Neutralizing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of new anti-HIV drugs with a novel mechanism of action is still required. A human cell surface protein, CD4, is a primary receptor for HIV-1 entry, and we have developed small-molecule CD4-competitive HIV-1 entry inhibitors, including CD4 mimics. CD4 mimics bind to a viral envelope protein, gp120, and cause a conformational change. Combinational use of CD4 mimics with CD4-induced antibodies, which recognize the exposed regions of gp120 induced by the CD4/CD4 mimic binding, shows a synergistic effect of anti-HIV activity. Therefore, we envisioned that antibody-drug conjugates (ADCs) of CD4 mimics and CD4-induced antibodies would effectively inhibit virus entry. Herein, ADCs of CD4 mimics and CD4-induced antibodies were designed and synthesized, and their anti-HIV-1 activities were evaluated. As a result, several synthesized ADCs exhibited 7- to 10-fold higher anti-HIV-1 activity than that of the parent antibodies, although there remains significant room for improvement in these ADCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD4 AntigensHIV-1ImmunoconjugatesAntibodies, NeutralizingVirus InternalizationAnti-HIV AgentsHIV Fusion InhibitorsHumansHIV Envelope Protein gp120Structure-Activity Relationship

Substanzen

CD4 AntigensImmunoconjugatesHIV Envelope Protein gp120Antibodies, NeutralizingAnti-HIV AgentsHIV Fusion Inhibitors

Autor:innen und Institutionen

  • Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062, Japan.
  • Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 5-1 Oe Honma…

ORCID-Profile: Kohei Tsuji, Hirokazu Tamamura

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Support for Pioneering Research Initiated by the Next Generation

Zitieren

APA

Miura, Y., Tsuji, K., Kobayakawa, T., Matsumoto, K., Kuwata, T., Matsuzaki, R., Matsushita, S., & Tamamura, H. (2025). Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors. Journal of Medicinal Chemistry, 68(24), 25899-25911. https://doi.org/10.1021/acs.jmedchem.5c01552

Vancouver

Miura Y, Tsuji K, Kobayakawa T, Matsumoto K, Kuwata T, Matsuzaki R, et al. Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors. Journal of Medicinal Chemistry. 2025;68(24):25899-25911. doi:10.1021/acs.jmedchem.5c01552

BibTeX
@article{Miura2025,
  author = {Miura, Yutaro and Tsuji, Kohei and Kobayakawa, Takuya and Matsumoto, Kaho and Kuwata, Takeo and Matsuzaki, Riku and Matsushita, Shuzo and Tamamura, Hirokazu},
  title = {Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {24},
  pages = {25899--25911},
  doi = {10.1021/acs.jmedchem.5c01552}
}
Kostenlos starten →